Abstract
In drug discovery research in the oncology field, in vitro models, ex vivo platforms and tumor-on-a-chip models using patient-derived tissues that provide highly predictive data for clinical settings have been developed. These advancements enable the elucidation of mechanisms of action and patient stratification, leading to rapid evaluation of new drug candidates and efficient translational research. Additionally, the use of high-content imaging technology and biobanks having various cancer tissues offers significant value to drug discovery research. By integrating these technologies into a comprehensive platform, it contributes to the 3Rs（refinement, replacement, and reduction of animal use） and simultaneously improves the success rates in clinical trials, reduces costs, and then enhances the efficiency of the pharmaceutical development process, resulting in accelerating the approval process of innovative new drugs.
